Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Insulin Delivery Nov 19 | 2020Lilly Partners with Ypsomed for AID System; Tidepool Lays Off 40% of StaffPurchase Blast
$599
Posted in: SGLT2i Nov 18 | 2020Lexicon @ Stifel; First Presentation Since SOLOIST and SCORED ResultsPurchase Blast
$599
Posted in: Glucose Monitoring, SGLT2i Nov 18 | 2020EMPA-REG OUTCOME Post Hoc Analysis; Abbott Sponsors ADA Health Equity Initiative; Nemaura Launches BEAT Platform and Updated Company Website Ahead of US proBEAT LaunchPurchase Blast
$599
Posted in: GLP-1RA Nov 17 | 2020SUSTAIN FORTE Topline Results: Ozempic 2.0mg Doubles the Dose but not the EfficacyPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Nov 16 | 2020FDA Accepts IND for Lilly/Dicerna Cardiometabolic Asset; Gilead/Novo Announce Ph2 PoC NASH Results; Biocorp Launches Mallya in Europe; Nemaura Q3 '20 Earnings Update; Diabeloop Partners for AID System in JapanPurchase Blast
$599
Posted in: Other Nov 13 | 2020Omecamtiv Misses on Primary Outcome Components, Hits on LVEF <28% Subgroup; GALACTIC-HF @ AHA 2020Purchase Blast
$599
Posted in: Glucagon, Glucose Monitoring Nov 12 | 2020Zealand and Dario Q3 '20 Earnings Updates; Tidepool Completes Loop Human Factors Validation StudyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 12 | 2020Medtronic Launches InPen with Integrated Guardian ConnectPurchase Blast
$599
Posted in: Glucagon, Other, SGLT2i Nov 09 | 2020EMPEROR-Reduced Filed with EMA; November 2020 CHMP Agenda; Bayer Submits Finerenone to FDA and EMA; Xeris Q3 '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin Nov 09 | 2020Oramed Ph3 Oral Insulin Program Initiated; Filing Timeline UnclearPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA Nov 06 | 2020Novo to Acquire Emisphere Technologies; Mylan Q3 '20 Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, SGLT2i Nov 05 | 2020AZ, Provention Bio, Teva, and BD Q3 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Insulin Delivery Nov 05 | 2020Lilly Invests in Early-Stage Glucose-Responsive Insulin Company; Novo Presents Full STEP 3 Results; Lifescan Hires New Head of Marketing; New CymaBay GPR119 Hypo Prevention TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Nov 04 | 2020Insulet, Mannkind, and Lannett Q3 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Nov 02 | 2020Novo/Gilead NASH PoC Data @ AASLD; Novo Q3 '20 London Earnings EventPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Other Oct 30 | 2020Novo to use PRV for Sema Obesity; Ph1 Glucose-responsive Insulin Trial Initiated; Novo Q3 '20 Earnings UpdatePurchase Blast